Client News

InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis Suppurativa

Abivax reports 2021 financial results and operations update

RedHill and Kukbo Enter Oral Opaganib License for COVID-19 in South Korea

Adrenomed Supervisory Board appoints Dr. Richard Jones as CEO

Temedica announces cooperation with Bristol Myers Squibb for the development of a digital companion for psoriasis patients

Newron announces 2021 financial results and provides outlook for 2022

AYOXXA receives fresh capital for commercial growth in Europe, US and Asia led by Prosnav Capital

Abivax reports promising ABX464 phase 2a one-year maintenance results in rheumatoid arthritis

InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting

NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets